Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTX·NASDAQ

$36.21

-1.7%
HealthcareBiotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$3.90B
EPS-1.6300
P/E Ratio-22.21
Earnings Date08/06/2026

ewtx

Shares Outstanding

Last Annual Value

102.93M

3-Year CAGR

24%

5-Year CAGR

16%

10-Year CAGR

8%

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. Competitors Analysis of shares-outstanding

EWTX · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
102.93M
17.3%15.8%N/A 
QURE logo
uniQure N.V.
NASDAQ:QURE
57.50M
6.4%4.2%8.7%
64.23M
14.6%36.7%N/A
59.20M
17.2%10.1%N/A
84.80M
23.7%48.1%61.1%
341.54M
16.0%11.5%N/A
66.50M
11.1%9.2%25.7%
61.97M
12.1%8.5%N/A
187.24M
29.8%17.9%22.4%
Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. Fair Value Envelope

EWTX · NASDAQ

Our analysis suggests that EWTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $36.21, this represents a potential HIDDEN relative to our calculated worth for Edgewise Therapeutics, Inc..

Intrinsic Value
Current Price: $36.21